EUVIMEDEUVIMED entdecken
Open Access

EPIC-1042 as a potent PTRF/Cavin1–caveolin-1 interaction inhibitor to induce PARP1 autophagic degradation and suppress temozolomide efflux for glioblastoma

Biao Hong, Eryan Yang, Dongyuan Su, Jiasheng Ju, Xiaoteng Cui, Qixue Wang, Fei Tong, Jixing Zhao, Shixue Yang, Chunchao Cheng, Lei Xin, Menglin Xiao und 6 weitere

Neuro-Oncology · 2024

DOI: 10.1093/neuonc/noad159 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2024. Verfasst von Biao Hong und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Tianjin Medical University General Hospital, Laboratory of Neuro-oncology, Tianjin Neurological Institute, Key Laboratory…. Hauptthemen laut MEDLINE: Glioblastoma. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Tianjin Key R&D Plan of Tianjin Science and Technology, Key-Area Research and Development Program of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Temozolomide (TMZ) treatment efficacy in glioblastoma is determined by various mechanisms such as TMZ efflux, autophagy, base excision repair (BER) pathway, and the level of O6-methylguanine-DNA methyltransferase (MGMT). Here, we reported a novel small-molecular inhibitor (SMI) EPIC-1042 (C20H28N6) with the potential to decrease TMZ efflux and promote PARP1 degradation via autolysosomes in the early stage.

Methods

EPIC-1042 was obtained from receptor-based virtual screening. Co-immunoprecipitation and pull-down assays were applied to verify the blocking effect of EPIC-1042. Western blotting, co-immunoprecipitation, and immunofluorescence were used to elucidate the underlying mechanisms of EPIC-1042. In vivo experiments were performed to verify the efficacy of EPIC-1042 in sensitizing glioblastoma cells to TMZ.

Results

EPIC-1042 physically interrupted the interaction of PTRF/Cavin1 and caveolin-1, leading to reduced secretion of small extracellular vesicles (sEVs) to decrease TMZ efflux. It also induced PARP1 autophagic degradation via increased p62 expression that more p62 bound to PARP1 and specially promoted PARP1 translocation into autolysosomes for degradation in the early stage. Moreover, EPIC-1042 inhibited autophagy flux at last. The application of EPIC-1042 enhanced TMZ efficacy in glioblastoma in vivo.

Conclusion

EPIC-1042 reinforced the effect of TMZ by preventing TMZ efflux, inducing PARP1 degradation via autolysosomes to perturb the BER pathway and recruitment of MGMT, and inhibiting autophagy flux in the later stage. Therefore, this study provided a novel therapeutic strategy using the combination of TMZ with EPIC-1042 for glioblastoma treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaHumansTemozolomideDacarbazineAntineoplastic Agents, AlkylatingCaveolin 1Cell Line, TumorDNA Repair EnzymesDNA Modification MethylasesAutophagyDrug Resistance, NeoplasmPoly (ADP-Ribose) Polymerase-1

Stichwörter der Autor:innen

AutophagyPARP1Small-molecular inhibitorTMZ efficacyTMZ efflux

Substanzen

TemozolomideDacarbazineAntineoplastic Agents, AlkylatingCaveolin 1DNA Repair EnzymesDNA Modification MethylasesPARP1 protein, humanPoly (ADP-Ribose) Polymerase-1

Autor:innen und Institutionen

  • Department of Neurosurgery, Tianjin Medical University General Hospital, Laboratory of Neuro-oncology, Tianjin Neurological Institute, Key Laboratory of Post-Neuro Injury Neuro-Repair and Regeneration in Central Nervous…
  • Department of Neurosurgery, Affiliated Hospital of Hebei University, Baoding, China.
  • Department of Neuro-Oncology and Neurosurgery, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin'…
  • Tianjin Key Laboratory of Composite and Functional Materials, School of Materials Science and Engineering, Tianjin University, Tianjin, China.

ORCID-Profile: Chunsheng Kang

Förderung

  • National Natural Science Foundation of China
  • Tianjin Key R&D Plan of Tianjin Science and Technology
  • Key-Area Research and Development Program of Guangdong Province

Zitieren

APA

Hong, B., Yang, E., Su, D., Ju, J., Cui, X., Wang, Q., Tong, F., Zhao, J., Yang, S., Cheng, C., Xin, L., Xiao, M., Yi, K., Zhan, Q., Ding, Y., Xu, H., Cui, L., & Kang, C. (2024). EPIC-1042 as a potent PTRF/Cavin1–caveolin-1 interaction inhibitor to induce PARP1 autophagic degradation and suppress temozolomide efflux for glioblastoma. Neuro-Oncology. https://doi.org/10.1093/neuonc/noad159

Vancouver

Hong B, Yang E, Su D, Ju J, Cui X, Wang Q, et al. EPIC-1042 as a potent PTRF/Cavin1–caveolin-1 interaction inhibitor to induce PARP1 autophagic degradation and suppress temozolomide efflux for glioblastoma. Neuro-Oncology. 2024. doi:10.1093/neuonc/noad159

BibTeX
@article{Hong2024,
  author = {Hong, Biao and Yang, Eryan and Su, Dongyuan and Ju, Jiasheng and Cui, Xiaoteng and Wang, Qixue and Tong, Fei and Zhao, Jixing and Yang, Shixue and Cheng, Chunchao and Xin, Lei and Xiao, Menglin and Yi, Kaikai and Zhan, Qi and Ding, Yaqing and Xu, Hanyi and Cui, Longtao and Kang, Chunsheng},
  title = {EPIC-1042 as a potent PTRF/Cavin1–caveolin-1 interaction inhibitor to induce PARP1 autophagic degradation and suppress temozolomide efflux for glioblastoma},
  journal = {Neuro-Oncology},
  year = {2024},
  doi = {10.1093/neuonc/noad159}
}
Kostenlos starten →